Optimizing Oncology Commercialization: A Comparative Analysis of Pre- and Post- Launch Metrics

Nazim N Haider

Abstract: *Commercial success in oncology is crucial for driving innovation, ensuring patient access to cutting-edge treatments, and sustaining research and development efforts in the fight against cancer. This paper explores a comparative analysis of pre- and post-launch metrics in oncology, highlighting the importance of addressing market dynamics, access barriers, and competitive positioning for successful commercialization. Challenges faced by oncology therapies with high clinical success but poor commercial success, such as talimogene laherparepvec (T-VEC), are examined to illustrate the complexities of the oncology market. The use of real-world data sources, including electronic health records, patient registries, and claims data, is discussed in evaluating commercial metrics and optimizing strategies for oncology products. By understanding and leveraging pre- and post-launch metrics, pharmaceutical companies and healthcare providers can navigate the complexities of the oncology market, drive sustainable growth, and enhance patient outcomes.*

Keywords: commercialization, pre-launch metrics, post-launch metrics, competitive positioning, patient access, market share, key opinion leaders, patient outcomes

1. Introduction and Background

Commercial success in oncology is crucial as it drives innovation, ensures patient access to cutting-edge treatments, and sustains research and development efforts in the fight against cancer. The successful commercialization of oncology therapies not only supports the financial viability of pharmaceutical companies, but also fosters competition, leading to the development of more effective and targeted treatments [1]. Moreover, commercial success enables investment in precision medicine, personalized therapies, and supportive care services, ultimately improving outcomes for cancer patients. By translating scientific advancements into commercially viable products, oncology companies can significantly impact global health, healthcare sustainability, and the overall well-being of individuals affected by cancer [2].

An example of high clinical success but poor commercial success in oncology is talimogene laherparepvec (T-VEC), a genetically modified oncolytic virus therapy approved for advanced melanoma. Despite demonstrating efficacy in clinical trials and receiving FDA approval, T-VEC faced challenges in market penetration owing to complex administration requirements, limited efficacy in certain patient populations, reimbursement issues, and competition from other immunotherapy agents. The perception of using virus-based therapy for cancer treatment, concerns about safety, and the need for specialized administration further hindered its commercial success. These factors collectively illustrate a scenario in which a therapy with promising clinical outcomes struggled to achieve widespread adoption and commercial viability in the competitive oncology market, highlighting the importance of addressing market dynamics, access barriers, and competitive positioning for successful commercialization in oncology [3].

The purpose of this paper is to discuss the difference in pre- and post-launch metrics and highlight the different metrics used to track successful drug launches in oncology. The paper also shares various real-world datasets leveraged for pre- and post-launch metrics in oncology.

2. Literature Review

2.1 Differences in Pre and Post Launch Metrics

The differences between pre- and post-launch metrics in oncology lie in their focus and objectives. The key distinctions between the pre- and post-launch metrics in the context of oncology are as follows:
1) **Pre-Launch Metrics:**
- Focus: Pre-launch metrics primarily concentrate on preparing for the successful introduction of a new oncology product into the market [3].
- Objectives: The main objectives of pre-launch metrics are to assess market opportunities, understand the competitive landscape, establish key strategies, and ensure regulatory and compliance readiness [3] [4].
- Activities: Pre-launch metrics involve market research, target patient population analysis, KOL engagement, market access strategy development, payer landscape assessment, and regulatory compliance preparation [3] [5].
- Outcome: The outcome of pre-launch metrics is to lay a strong foundation for successful market entry, build awareness and anticipation, and align internal teams and external stakeholders for the launch [3] [6].

2) **Post-Launch Metrics:**
- Focus: Post-launch metrics shift the focus towards evaluating the performance and impact of oncology products in the market after their commercial introduction [3].
- Objectives: The key objectives of post-launch metrics are to monitor sales performance, assess market share, track prescription volume, evaluate patient adherence and persistence, and measure physician adoption rates [3] [4].
- Activities: Post-launch metrics involve analyzing patient access and utilization, assessing KOL influence, evaluating market access success, comparing

competitive positioning, and calculating return on investment [3] [5].

- Outcome: The outcome of post-launch metrics is to measure a product's market performance, identify areas for optimization, drive product growth, and make informed decisions to enhance market share and profitability [3] [6].

In summary, while pre-launch metrics focus on readiness and preparation for market entry, post-launch metrics shift towards evaluating real-world performance, market acceptance, and the commercial success of oncology products. By understanding and leveraging both pre- and post-launch metrics, pharmaceutical companies and healthcare providers can effectively navigate the complexities of the oncology market, optimize product strategies, and drive sustainable growth and success [3].

2.2 Pre-Launch Metrics

Commercial pre-launch metrics are essential for the successful introduction of a new oncology product into the market. Key commercial pre-launch metrics in oncology include the following:

- Market Research Insights: Market research insights provide valuable information on market dynamics, the competitor landscape, unmet needs, and potential opportunities in the oncology market. Understanding market research insights helps shape pre-launch strategies.
- Target Patient Population Analysis: This involves identifying and analyzing specific patient segments that are most likely to benefit from the new oncology product. Understanding the target patient population helps tailor marketing and access strategies.
- KOL Mapping and Engagement: KOL mapping involves identifying key opinion leaders in the oncology field who can influence treatment practices and product adoption. Engaging with KOLs pre-launch can help build advocacy and support for new products.
- Market Access Strategy Development: Market access strategy development focuses on planning the positioning, pricing, and reimbursement of new oncology products in the market. Developing a robust pre-launch market-access strategy is crucial for ensuring product availability and uptake.
- Payer Landscape Assessment: Payer landscape assessment involves evaluating the perspectives and requirements of payers, such as insurance companies and government agencies, regarding the reimbursement and coverage of the new oncology product. Understanding the payer landscape helps develop pricing and access strategies.
- Key Messaging and Positioning: Key messaging and positioning involve crafting clear and compelling messages that communicate the unique value proposition of a new oncology product to healthcare providers, patients, and other stakeholders. The development of key messaging and positioning pre-launches is essential for effective communication.
- Competitive Analysis: Competitive analysis assesses the strengths, weaknesses, and strategies of competitors in the oncology market. Understanding the pre-launch

competitive landscape helps in identifying differentiation opportunities and developing competitive positioning.

- Regulatory and Compliance Readiness: Regulatory and compliance readiness involves ensuring that the new oncology product complies with regulatory requirements and guidelines before launch. Regulatory-ready pre launches are essential for smooth market entry.
- Pre-Launch Marketing Activities: Pre-launch marketing activities include educational initiatives, awareness campaigns, and engagement programs conducted before the commercial launch of an oncology product. Effective pre-launch marketing activities help build anticipation and interest among stakeholders.
- Establishment of Key Performance Indicators (KPIs): Establishing performance indicators pre-launch helps in setting measurable goals and benchmarks for evaluating the success of the launch strategy. Defining KPIs enables the early tracking and monitoring of progress towards launch objectives.

By focusing on these commercial pre-launch metrics, pharmaceutical companies and healthcare providers can lay a strong foundation for the successful market entry of new oncology products. Strategic planning, stakeholder engagement, and market readiness are key elements in driving pre-launch activities and setting the stage for a successful commercial launch [3] [4] [5] [6].

2.3 Post Launch Metrics

Commercial post-launch metrics are critical for evaluating the performance and impact of new oncology products in the market. Key commercial post-launch metrics in oncology include the following:

- Sales Performance: Sales performance metrics track the revenue generated by oncology products post-launch. Monitoring sales performance helps to assess market uptake, demand trends, and revenue growth.
- Market Share: Market share metrics measure the percentage of the oncology market captured by the new product compared with competitors. Monitoring market share helps to evaluate product competitiveness and positioning.
- Prescription Volume: Prescription volume metrics quantify the number of prescriptions written for oncology products by healthcare providers. Monitoring prescription volumes provides insight into product adoption and utilization.
- Patient Adherence and Persistence: Patient adherence and persistence metrics assess the extent to which patients continue treatment with oncology products over time. High adherence and persistence rates indicate patient satisfaction and treatment effectiveness.
- Physician Adoption Rate: Physician adoption rate measures the percentage of healthcare providers who prescribe or recommend oncology products. Increasing physician adoption is crucial for driving product uptake and market penetration.
- Patient Access and Utilization: Patient access and utilization metrics evaluate the ease of patient access to oncology products and the level of patient utilization post-launch. Monitoring patient access and utilization helps assess product demand and market acceptance.

- Key Opinion Leader (KOL) Influence: KOL influence metrics assess the impact of key opinion leaders in promoting and endorsing oncology products. Tracking KOL influences gauge advocacy and support within the medical community.
- Market Access Success: Market access success metrics evaluate a product's formulary placement, reimbursement status, and access to key accounts post-launch. Assessing market access success is essential for ensuring broad product availability.
- Competitive Positioning: Competitive positioning metrics compare the performance and market positioning of an oncology product against competitors.

Understanding competitive positioning helps to identify strengths, weaknesses, and differentiation opportunities.
- Return on Investment (ROI): ROI metrics calculate the return on investment from commercial activities and marketing initiatives post-launch. Evaluating ROI helps to assess the effectiveness of marketing strategies and resource allocation.

By monitoring and analyzing these commercial post-launch metrics, pharmaceutical companies and healthcare providers can evaluate the success of new oncology products in the market, identify areas for improvement, and optimize strategies to drive product growth and market share [3] [4] [5] [6].


Figure 1: CMK Select. Commercial Pre and Post Launch Metrics

2.4 Use of Real-World Data

Real-world data (RWD) plays a crucial role in evaluating commercial pre- and post-launch metrics in oncology. During the pre-launch period, RWD sources such as electronic health records (EHRs), claims data, and patient registries provide valuable insights into disease prevalence, treatment patterns, and unmet needs within specific oncology populations [7]. These data sources help pharmaceutical companies to identify target patient populations, understand treatment pathways, assess market dynamics, and optimize commercial strategies prior to product launch. Post-launch, RWD continues to be instrumental in monitoring real-world effectiveness, safety profiles, treatment adherence, and patient outcomes associated with oncology therapies [9]. Longitudinal data from EHRs, patient-reported outcomes, and disease registries enable the ongoing assessment of treatment response,

healthcare utilization, and comparative effectiveness, guiding post-launch commercial decisions, market access strategies, and lifecycle management initiatives for oncology products [8].

Moreover, RWD sources, such as electronic medical records, patient-generated health data, and mobile health applications, offer real-time insights into treatment response, adverse events, and patient-reported outcomes, facilitating proactive pharmacovigilance, personalized medicine approaches, and value-based care initiatives in oncology. By leveraging RWD analytics, pharmaceutical companies can track product uptake, market share trends, treatment patterns, and patient outcomes in real-world settings, enabling agile commercial decision making, targeted marketing strategies, and evidence-based value propositions for oncology products. The integration of diverse RWD sources, advanced analytics, and

real-world evidence generation methodologies enhances the commercial success of oncology therapies by providing actionable insights, optimizing market access strategies, and demonstrating the value of innovative treatments in improving patient outcomes and healthcare delivery.

3. Conclusion

The paper emphasizes the critical role of optimizing oncology commercialization with pre- and post-launch metrics, real-world data, and strategic decision-making. By leveraging these metrics and data sources, pharmaceutical companies can evaluate the success of new oncology products in the market, identify areas for improvement, and drive product growth and market share. Additionally, the integration of real-world data analytics and evidence generation methodologies enhances the commercial success of oncology therapies by providing actionable insights, optimizing market access strategies, and demonstrating the value of innovative treatments in improving patient outcomes and healthcare delivery. Ultimately, the successful commercialization of oncology therapies not only supports the financial viability of pharmaceutical companies but also fosters competition, leading to the development of more effective and targeted treatments, thereby improving outcomes for cancer patients, and impacting global health and healthcare sustainability.

References

[1] Zhang, Z., Zhou, L., Xie, N., Nice, E., Zhang, T., Cui, Y., & Huang, C. (2020). Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy, 5. https://doi.org/10.1038/s41392-020-00213-8.

[2] Valachis, A., Polyzos, N., Nearchou, A., Lind, P., & Mauri, D. (2012). Financial relationships in economic analyses of targeted therapies in oncology.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 12, 1316-20 . https://doi.org/10.1200/JCO.2011.38.6078.

[3] Toniatti, C., Jones, P., Graham, H., Pagliara, B., & Draetta, G. (2014). Oncology drug discovery: planning a turnaround. Cancer discovery, 4(4), 397–404. https://doi.org/10.1158/2159-8290.CD-13-0452.

[4] DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013). Clinical approval success rates for investigational cancer drugs. Clinical pharmacology and therapeutics, 94(3), 329–335. https://doi.org/10.1038/clpt.2013.117.

[5] Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2019). Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA internal medicine, 179(7), 906–913. https://doi.org/10.1001/jamainternmed.2019.0462.

[6] Prasad, V., & Mailankody, S. (2017). Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA internal medicine, 177(11), 1569–1575. https://doi.org/10.1001/jamainternmed.2017.3601.

[7] Dusetzina, S. B., Tyree, S., Meyer, A. M., Meyer, A., Green, L., & Carpenter, W. R. (2014). Linking Data for Health Services Research: A Framework and Instructional Guide. Agency for Healthcare Research and Quality (US).

[8] Schneeweiss, S., & Avorn, J. (2005). A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of clinical epidemiology, 58(4), 323–337. https://doi.org/10.1016/j.jclinepi.2004.10.012

[9] Gliklich, R. E., Dreyer, N. A., & Leavy, M. B. (Eds.). (2014). Registries for Evaluating Patient Outcomes: A User's Guide. (3rd ed.). Agency for Healthcare Research and Quality (US).

[10] CMK Select. (2017). Ensuring Launch Success with KPIs. CMKSelect. https://www.cmkselect.com/knowledge-insight/ensuring-launch-success-with-kpis/